AP1497A - Methods and compositions to enhance white blood cell count. - Google Patents
Methods and compositions to enhance white blood cell count.Info
- Publication number
- AP1497A AP1497A APAP/P/2001/002221A AP2001002221A AP1497A AP 1497 A AP1497 A AP 1497A AP 2001002221 A AP2001002221 A AP 2001002221A AP 1497 A AP1497 A AP 1497A
- Authority
- AP
- ARIPO
- Prior art keywords
- nitrogen
- formula
- atoms
- methods
- blood cell
- Prior art date
Links
- 210000000265 leukocyte Anatomy 0.000 title abstract 3
- 238000004820 blood count Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 4
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 125000002947 alkylene group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000004122 cyclic group Chemical group 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical group SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000000468 ketone group Chemical group 0.000 abstract 1
- 125000005647 linker group Chemical group 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 229920000768 polyamine Polymers 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/547—Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11825599P | 1999-02-02 | 1999-02-02 | |
| PCT/CA2000/000104 WO2000045814A1 (en) | 1999-02-02 | 2000-02-02 | Methods and compositions to enhance white blood cell count |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AP2001002221A0 AP2001002221A0 (en) | 2001-09-30 |
| AP1497A true AP1497A (en) | 2005-11-20 |
Family
ID=22377471
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| APAP/P/2001/002221A AP1497A (en) | 1999-02-02 | 2000-02-02 | Methods and compositions to enhance white blood cell count. |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US6365583B1 (enExample) |
| EP (1) | EP1148875B1 (enExample) |
| JP (2) | JP4968868B2 (enExample) |
| KR (1) | KR100643553B1 (enExample) |
| CN (1) | CN1310642C (enExample) |
| AP (1) | AP1497A (enExample) |
| AT (1) | ATE268597T1 (enExample) |
| AU (2) | AU772979B2 (enExample) |
| BR (1) | BR0007924A (enExample) |
| CA (1) | CA2361587C (enExample) |
| CZ (1) | CZ20012698A3 (enExample) |
| DE (1) | DE60011391T2 (enExample) |
| DK (1) | DK1148875T3 (enExample) |
| ES (1) | ES2222174T3 (enExample) |
| HK (1) | HK1038319B (enExample) |
| HU (1) | HUP0200100A3 (enExample) |
| IL (1) | IL144400A (enExample) |
| MX (1) | MXPA01007801A (enExample) |
| NO (1) | NO20013770L (enExample) |
| NZ (1) | NZ513602A (enExample) |
| PT (1) | PT1148875E (enExample) |
| SI (1) | SI1148875T1 (enExample) |
| TR (1) | TR200102239T2 (enExample) |
| WO (1) | WO2000045814A1 (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6506770B1 (en) | 1996-06-06 | 2003-01-14 | Anormed, Inc. | Antiviral compounds |
| CN100335478C (zh) * | 1999-12-17 | 2007-09-05 | 阿诺麦德股份有限公司 | 结合趋化因子受体的杂环化合物 |
| US8435939B2 (en) | 2000-09-05 | 2013-05-07 | Biokine Therapeutics Ltd. | Polypeptide anti-HIV agent containing the same |
| DK1317451T3 (da) * | 2000-09-15 | 2006-12-18 | Anormed Inc | Kemokinreceptorbindende heterocykliske forbindelser |
| NZ524421A (en) * | 2000-09-15 | 2005-02-25 | Anormed Inc | Chemokine receptor binding heterocyclic compounds |
| EP1322626B1 (en) | 2000-09-29 | 2008-11-05 | Anormed Inc. | Process for preparation of n-1 protected n ring nitrogen containing cyclic polyamines and products thereof |
| US7169750B2 (en) * | 2001-07-31 | 2007-01-30 | Anormed, Inc. | Methods to mobilize progenitor/stem cells |
| EP2371361B1 (en) * | 2001-07-31 | 2019-08-07 | Genzyme Corporation | Methods to mobilize progenitor/stem cells |
| US6825351B2 (en) * | 2001-09-12 | 2004-11-30 | Anormed, Inc. | Synthesis of enantiomerically pure amino-substituted fused bicyclic rings |
| US7354932B2 (en) * | 2001-12-21 | 2008-04-08 | Anormed, Inc. | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
| MXPA04006136A (es) * | 2001-12-21 | 2004-11-01 | Anormed Inc | Compuestos heterociclicos que se unen a receptor de quimiocina con eficacia incrementada. |
| EP1541585B1 (en) | 2002-08-27 | 2013-01-30 | Biokine Therapeutics Ltd. | Cxcr4 antagonist and use thereof |
| WO2004091518A2 (en) | 2003-04-11 | 2004-10-28 | Anormed Inc. | Cxcr4 chemokine receptor binding compounds |
| US7501518B2 (en) * | 2003-04-22 | 2009-03-10 | Genzyme Corporation | Methods of making 2,6-diaryl piperidine derivatives |
| EP2374804A1 (en) * | 2003-04-22 | 2011-10-12 | Genzyme Corporation | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
| EP1708703A4 (en) * | 2003-12-11 | 2008-04-09 | Anormed Inc | CHEMOKIN RECEPTOR BINDING COMPOUNDS |
| US7498346B2 (en) * | 2003-12-11 | 2009-03-03 | Genzyme Corporation | Chemokine receptor binding compounds |
| WO2006020891A2 (en) * | 2004-08-13 | 2006-02-23 | Anormed Inc. | Chemokine combinations to mobilize progenitor/stem cells |
| CA2612325A1 (en) * | 2005-06-15 | 2006-12-28 | Anormed Inc. | Chemokine receptor binding compounds |
| EP1924265A4 (en) * | 2005-08-16 | 2010-06-02 | Genzyme Corp | COMPOUNDS BINDING TO CHEMOKINE RECEPTORS |
| JP2009527552A (ja) * | 2006-02-24 | 2009-07-30 | ジェンザイム・コーポレーション | 血流の増加および組織再生の促進またはそのいずれかのための方法 |
| AR063470A1 (es) * | 2006-08-02 | 2009-01-28 | Genzyme Corp | Terapia combinada |
| AR062271A1 (es) * | 2006-08-07 | 2008-10-29 | Genzyme Corp | Uso de una cantidad efectiva de al menos un inhibidor de cxcr4, al menos un agonista de cxcr2 y g-csf para movilizar las celulas progenitoras y/o celulas madre |
| CA2673719C (en) * | 2006-12-21 | 2018-07-24 | Biokine Therapeutics Ltd. | T-140 peptide analogs having cxcr4 super-agonist activity for bone marrow recovery |
| EP2396023A2 (en) | 2009-02-11 | 2011-12-21 | Yeda Research and Development Co. Ltd. | Short beta-defensin-derived peptides |
| EP2442822B1 (en) | 2009-06-14 | 2014-03-05 | Biokine Therapeutics Ltd. | Peptide therapy for increasing platelet levels |
| CA2807552A1 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| PL2709991T3 (pl) * | 2011-05-16 | 2021-04-06 | Genzyme Corporation | Zastosowanie antagonistów CXCR4 w leczeniu zespołu WHIM, mielokateksji, neutropenii i limfocytopenii |
| WO2013160895A1 (en) | 2012-04-24 | 2013-10-31 | Biokine Therapeutics Ltd. | Peptides and use thereof in the treatment of large cell lung cancer |
| CN116196426A (zh) | 2015-07-16 | 2023-06-02 | 百欧肯治疗有限公司 | 治疗癌症的组合物及方法 |
| EP3389634B1 (en) | 2015-12-14 | 2021-10-06 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| JP6958820B2 (ja) | 2015-12-14 | 2021-11-02 | エックス４ ファーマシューティカルズ， インコーポレイテッド | がんを処置する方法 |
| JP7055380B2 (ja) | 2015-12-22 | 2022-04-18 | エックス４ ファーマシューティカルズ， インコーポレイテッド | 免疫不全疾患を処置するための方法 |
| AU2017222495B2 (en) | 2016-02-23 | 2019-08-08 | Biolinerx Ltd. | Methods of treating acute myeloid leukemia |
| WO2017177230A1 (en) | 2016-04-08 | 2017-10-12 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| EP3808748A1 (en) | 2016-06-21 | 2021-04-21 | X4 Pharmaceuticals, Inc. | Substituted piperidines as cxcr4-inhibitors |
| CN109640988A (zh) | 2016-06-21 | 2019-04-16 | X4 制药有限公司 | Cxcr4抑制剂及其用途 |
| CA3027500A1 (en) | 2016-06-21 | 2017-12-28 | X4 Pharmaceuticals, Inc. | Cxcr4 inhibitors and uses thereof |
| US10548889B1 (en) | 2018-08-31 | 2020-02-04 | X4 Pharmaceuticals, Inc. | Compositions of CXCR4 inhibitors and methods of preparation and use |
| CN109187337A (zh) * | 2018-09-10 | 2019-01-11 | 南京工业职业技术学院 | 一种筛选强韧性FeAl晶界的方法 |
| JP2023517956A (ja) | 2020-03-10 | 2023-04-27 | エックス４ ファーマシューティカルズ， インコーポレイテッド | 好中球減少症を処置する方法 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0434385A2 (en) * | 1989-12-21 | 1991-06-26 | Johnson Matthey Public Limited Company | Use of macrocyclic nitrogen containing compounds for the treatment of retroviral infections |
| WO1995018808A1 (en) * | 1994-01-11 | 1995-07-13 | Johnson Matthey Public Limited Company | Cyclic polyamines |
| WO2000002870A1 (en) * | 1998-07-08 | 2000-01-20 | Anormed Inc. | Antiviral macrocyclic compounds |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4810643A (en) | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
| GB9126677D0 (en) | 1991-12-16 | 1992-02-12 | Johnson Matthey Plc | Improvements in chemical compounds |
| US5612478A (en) | 1995-03-30 | 1997-03-18 | Johnson Matthey Plc | Process for preparing 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane |
| US5606053A (en) | 1995-05-02 | 1997-02-25 | Johnson Matthey Plc | Process for preparing 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane |
| GB9511357D0 (en) | 1995-06-06 | 1995-08-02 | Johnson Matthey Plc | Improved antiviral compounds |
| EP1133291B1 (en) * | 1998-11-17 | 2006-01-11 | Smithkline Beecham Corporation | Cyclic polyamines for treating thrombocytopenia |
-
2000
- 2000-02-01 US US09/495,298 patent/US6365583B1/en not_active Expired - Lifetime
- 2000-02-02 CN CNB008033285A patent/CN1310642C/zh not_active Expired - Fee Related
- 2000-02-02 AU AU25278/00A patent/AU772979B2/en not_active Ceased
- 2000-02-02 TR TR2001/02239T patent/TR200102239T2/xx unknown
- 2000-02-02 WO PCT/CA2000/000104 patent/WO2000045814A1/en not_active Ceased
- 2000-02-02 CZ CZ20012698A patent/CZ20012698A3/cs unknown
- 2000-02-02 EP EP00903441A patent/EP1148875B1/en not_active Expired - Lifetime
- 2000-02-02 HK HK02100103.2A patent/HK1038319B/en not_active IP Right Cessation
- 2000-02-02 PT PT00903441T patent/PT1148875E/pt unknown
- 2000-02-02 ES ES00903441T patent/ES2222174T3/es not_active Expired - Lifetime
- 2000-02-02 BR BR0007924-3A patent/BR0007924A/pt not_active Application Discontinuation
- 2000-02-02 KR KR1020017009649A patent/KR100643553B1/ko not_active Expired - Fee Related
- 2000-02-02 AT AT00903441T patent/ATE268597T1/de not_active IP Right Cessation
- 2000-02-02 IL IL144400A patent/IL144400A/en not_active IP Right Cessation
- 2000-02-02 DE DE60011391T patent/DE60011391T2/de not_active Expired - Lifetime
- 2000-02-02 SI SI200030444T patent/SI1148875T1/xx unknown
- 2000-02-02 DK DK00903441T patent/DK1148875T3/da active
- 2000-02-02 NZ NZ513602A patent/NZ513602A/en unknown
- 2000-02-02 AP APAP/P/2001/002221A patent/AP1497A/en active
- 2000-02-02 CA CA2361587A patent/CA2361587C/en not_active Expired - Fee Related
- 2000-02-02 MX MXPA01007801A patent/MXPA01007801A/es not_active IP Right Cessation
- 2000-02-02 HU HU0200100A patent/HUP0200100A3/hu unknown
- 2000-02-02 JP JP2000596934A patent/JP4968868B2/ja not_active Expired - Fee Related
-
2001
- 2001-08-01 NO NO20013770A patent/NO20013770L/no not_active Application Discontinuation
-
2002
- 2002-01-04 US US10/039,150 patent/US6670354B2/en not_active Expired - Lifetime
-
2004
- 2004-08-13 AU AU2004203847A patent/AU2004203847B2/en not_active Ceased
-
2011
- 2011-02-04 JP JP2011023235A patent/JP2011088937A/ja not_active Withdrawn
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0434385A2 (en) * | 1989-12-21 | 1991-06-26 | Johnson Matthey Public Limited Company | Use of macrocyclic nitrogen containing compounds for the treatment of retroviral infections |
| WO1995018808A1 (en) * | 1994-01-11 | 1995-07-13 | Johnson Matthey Public Limited Company | Cyclic polyamines |
| WO2000002870A1 (en) * | 1998-07-08 | 2000-01-20 | Anormed Inc. | Antiviral macrocyclic compounds |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AP1497A (en) | Methods and compositions to enhance white blood cell count. | |
| LUC00139I1 (enExample) | ||
| EA200300792A1 (ru) | Хиназолины в качестве ингибиторов ммр-13 | |
| PT928788E (pt) | Compostos farmaceuticamente activos | |
| DE69935718D1 (de) | Antidiabetische medikamente | |
| ES8308835A1 (es) | Un procedimiento para la preparacion de derivados de etanola-mina. | |
| DK0485219T3 (da) | Lægemidler til forebyggelse og behandling af kredsløbsorgansygdomme indeholdende spiro-3-heteroazolidinforbindelser | |
| PL353494A1 (en) | Novel a-500359 derivatives | |
| EA200001157A2 (ru) | Новые замещенные производные (дигидро)бензоксазина и (дигидро)бензотиазина, способ их получения и содержащие их фармацевтические композиции | |
| WO2007106063A3 (en) | Methods for increasing blood flow and/or promoting tissue regeneration | |
| NZ336876A (en) | Process for preparation of 4-H-4-oxo-quinolizine-3-carboxylic acid derivatives |